Alexander Drzezga

Active 1999–2025

195
Papers
24,139
Citations
87
h-index
181
i10-index

Citations

Citations per year for Alexander Drzezga1949: 1 citations1982: 1 citations1983: 1 citations1986: 1 citations1998: 1 citations1999: 1 citations2000: 2 citations2001: 7 citations2002: 21 citations2003: 50 citations2004: 40 citations2005: 67 citations2006: 77 citations2007: 102 citations2008: 116 citations2009: 164 citations2010: 167 citations2011: 187 citations2012: 225 citations2013: 233 citations2014: 245 citations2015: 220 citations2016: 296 citations2017: 359 citations2018: 352 citations2019: 956 citations2020: 897 citations2021: 1,067 citations2022: 919 citations2023: 726 citations2024: 1,128 citations2025: 643 citations2026: 32 citations1950–1981: no citations, so these years are not shown1984–1985: no citations, so these years are not shown1987–1997: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,926 citing papers, 21.8% of this breakdownGermany: 1,385 citing papers, 10.3% of this breakdownUnited Kingdom: 1,044 citing papers, 7.8% of this breakdownChina: 1,008 citing papers, 7.5% of this breakdownItaly: 695 citing papers, 5.2% of this breakdownNetherlands: 628 citing papers, 4.7% of this breakdownSweden: 587 citing papers, 4.4% of this breakdownFrance: 491 citing papers, 3.6% of this breakdownCanada: 477 citing papers, 3.5% of this breakdownSpain: 442 citing papers, 3.3% of this breakdownSwitzerland: 439 citing papers, 3.2% of this breakdownAustralia: 406 citing papers, 3% of this breakdown
0%21.8%Other 21.7%

Fields

  • Medicine67.6%
  • Neuroscience22.8%
  • Biochemistry, Genetics and Molecular Biology4%
  • Computer Science1.5%
  • Psychology1.3%
  • Engineering0.6%
  • Other2.2%

Topics

  • Dementia and Cognitive Impairment Research11.2%
  • Alzheimer's disease research and treatments10.9%
  • Functional Brain Connectivity Studies7.3%
  • Medical Imaging Techniques and Applications3.1%
  • Radiopharmaceutical Chemistry and Applications3%
  • Prostate Cancer Treatment and Research2.9%
  • Other61.6%

Coauthors

All papers

Open in search
  1. Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wiesje M. van der Flier, Lisa Ford, Stefan Förster, Juan Fortea, Nadia Foskett, Kristian Steen Frederiksen, Yvonne Freund‐Levi, Giovanni B. Frisoni, Lutz Froelich, Tomasz Gabryelewicz, Kiran Dip Gill, Olymbia Gkatzima, Estrella Gómez‐Tortosa, Mark Forrest Gordon, Timo Grimmer, Harald Hampel, Lucrezia Hausner, Sabine Hellwig, Sanna‐Kaisa Herukka, Helmut Hildebrandt, Lianna Ishihara, Adrian Ivanoiu, William J. Jagust, Peter Johannsen, Ramesh Kandimalla, Elisabeth Kapaki, Aleksandra Klimkowicz‐Mrowiec, William E. Klunk, Sebastian Köhler, Norman Koglin, Johannes Kornhuber, Milica G. Kramberger, Koen Van Laere, Susan Landau, Dong Young Lee, Mony J. de Leon, Viviana Lisetti, Alberto Lleó, Karine Madsen, Wolfgang Maier, Jan Marcusson, Niklas Mattsson, Alexandre de Mendonça, Olga Meulenbroek, Philipp T. Meyer, Mark A. Mintun, Vincent Mok, José Luís Molinuevo, Hanne M. Møllergård, John C. Morris, Barbara Mroczko, Stefan Van der Mussele, Duk L. Na, Andrew B. Newberg, Agneta Nordberg, Arto Nordlund, Gerald Novak, George P. Paraskevas, Lucilla Parnetti, Gayan Perera, Oliver Peters, Julius Popp, Sudesh Prabhakar, Gil D. Rabinovici, Inez H.G.B. Ramakers, Lorena Rami, Catarina R. Oliveira, Juha O. Rinne, Karen M. Rodrigue, Eloy Rodríguez‐Rodríguez and 29 more - JAMA 2015 cited by 1,635

  2. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Drzezga - The Lancet Neurology 2020 cited by 531

  3. Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ann D. Cohen, Alisha Daniels, Marion Delarue, Mira Didic, Alexander Drzezga, Bruno Dubois, Marie Eckerström, Laura L. Ekblad, Sebastiaan Engelborghs, Stéphane Epelbaum, Anne M. Fagan, Yong Fan, Tormod Fladby, Adam Fleisher, Wiesje M. van der Flier, Stefan Förster, Juan Fortea, Kristian Steen Frederiksen, Yvonne Freund‐Levi, Lars Frings, Giovanni B. Frisoni, Lutz Fröhlich, Tomasz Gabryelewicz, Hermann‐Josef Gertz, Kiran Dip Gill, Olymbia Gkatzima, Estrella Gómez‐Tortosa, Timo Grimmer, Eric Guedj, Christian Habeck, Harald Hampel, Ron Handels, Oskar Hansson, Lucrezia Hausner, Sabine Hellwig, Michael T. Heneka, Sanna‐Kaisa Herukka, Helmut Hildebrandt, John R. Hodges, Jakub Hort, Chin‐Chang Huang, Ane Iriondo, Yoshiaki Itoh, Adrian Ivanoiu, William J. Jagust, Frank Jessen, Peter Johannsen, Keith A. Johnson, Ramesh Kandimalla, Elisabeth Kapaki, Silke Kern, Lena Kilander, Aleksandra Klimkowicz‐Mrowiec, William E. Klunk, Norman Koglin, Johannes Kornhuber, Milica G. Kramberger, Hung‐Chou Kuo, Koen Van Laere, Susan Landau, Brigitte Landeau, Dong Young Lee, Mony J. de Leon, Cristian E. Leyton, Kun‐Ju Lin, Alberto Lleó, Malin Löwenmark, Karine Madsen, Wolfgang Maier, Jan Marcusson and 83 more - JAMA Neurology 2022 cited by 288

  4. Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Günter U. Höglinger, Jochen Herms, Christian Haass, Matthias Brendel - Science Translational Medicine 2021 cited by 271

  5. German Multicenter Study Investigating177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2016 cited by 832

  6. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0

    Authors: , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2018 cited by 535

  7. Prevalence of Amyloid PET Positivity in Dementia Syndromes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Koen Van Laere, Alexander Drzezga, Stefan Förster, Timo Grimmer, Pascual Sánchez‐Juan, J.M. Carril, Vincent Mok, Vincent Camus, William E. Klunk, Ann D. Cohen, Philipp T. Meyer, Sabine Hellwig, Andrew B. Newberg, Kristian Steen Frederiksen, Adam Fleisher, Mark A. Mintun, David A. Wolk, Agneta Nordberg, Juha O. Rinne, Gaël Chételat, Alberto Lleó, Rafael Blesa, Juan Fortea, Karine Madsen, Karen M. Rodrigue, David J. Brooks - JAMA 2015 cited by 666

  8. Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kai Bötzel, Joseph Claßen, Peter Bartenstein, Victor L. Villemagne, Johannes Levin, Günter U. Höglinger, Alexander Drzezga, John Seibyl, Osama Sabri - JAMA Neurology 2020 cited by 253

  9. 18F-FDG PET Imaging in Neurodegenerative Dementing Disorders: Insights into Subtype Classification, Emerging Disease Categories, and Mixed Dementia with Copathologies

    Authors: , , , , - Journal of Nuclear Medicine 2022 cited by 164

  10. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2020 cited by 257

  11. Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raquel Lemos, Sebastiaan Engelborghs, Stefan Van der Mussele, The Alzheimer’s Disease Neuroimaging Initiative, Yvonne Freund‐Levi, Åsa K. Wallin, Harald Hampel, Wiesje M. van der Flier, Philip Scheltens, Pieter Jelle Visser - Brain 2015 cited by 393

  12. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0

    Authors: , , , , , , , , , , , , - Journal of Nuclear Medicine 2016 cited by 258

  13. Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias

    Authors: , , , , , , , , , , , , , , , , , - Journal of Nuclear Medicine 2008 cited by 723

  14. Networks of tau distribution in Alzheimer’s disease

    Authors: , , , , , , , , , , , - Brain 2017 cited by 179

  15. Cortical [18F]PI‐2620 Binding Differentiates Corticobasal Syndrome Subtypes

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Movement Disorders 2021 cited by 87

  16. Selective changes of resting-state networks in individuals at risk for Alzheimer's disease

    Authors: , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2007 cited by 1,025

  17. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F‐fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus

    Authors: , , , , , , , , - European Journal of Neurology 2018 cited by 211

  18. Metabolic connectivity: methods and applications

    Authors: , , - Current Opinion in Neurology 2017 cited by 164

  19. The default mode network and cognition in Parkinson's disease: A multimodal resting‐state network approach

    Authors: , , , , , , , , , , - Human Brain Mapping 2021 cited by 91

  20. Network degeneration in Parkinson’s disease: multimodal imaging of nigro-striato-cortical dysfunction

    Authors: , , , , , , , , , , , - Brain 2020 cited by 119

  21. Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer

    Authors: , , , , , , , , , , , , , - Molecular Imaging and Biology 2015 cited by 362

  22. 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

    Authors: , , , , , , , , , , , , , - Theranostics 2019 cited by 160

  23. Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

    Authors: , , , , , , , , , , , , , - European Journal of Nuclear Medicine and Molecular Imaging 2018 cited by 126

  24. Centiloid recommendations for clinical context‐of‐use from the AMYPAD consortium

    Authors: , , , , , , , , , , , , , , , , - Alzheimer s & Dementia 2024 cited by 82